Astigmatism Market Summary

Key Highlights

• Regular astigmatism is generally corrected effectively with spectacles or toric lenses, whereas irregular astigmatism can require specialty lenses or treatment of the underlying corneal disorder.
• Glaukos describes typical onset during the teenage years, with more aggressive progression often occurring before age 30.
• Approximately 90% of keratoconus cases are bilateral: However, the severity can differ substantially between the two eyes.
• Key companies active in the market include Johnson & Johnson Vision; Alcon; Bausch + Lomb; CooperVision; EssilorLuxottica; ZEISS; Glaukos; Euclid Vision; STAAR Surgical; RxSight; Carl Zeiss Meditec; HOYA; Menicon; SynergEyes; EyeYon Medical.

Factors Affecting Astigmatism Market Growth

Rising Prevalence of Refractive Errors

The increasing global burden of refractive disorders, including astigmatism, is a primary driver of market growth. A significant portion of the population experiences vision-related issues, leading to higher demand for corrective solutions such as glasses, contact lenses, and surgeries.

Growing Screen Time and Digital Eye Strain

The surge in digital device usage has contributed to visual impairments, including astigmatism. Prolonged exposure to screens is associated with eye strain and worsening vision conditions, thereby increasing the need for diagnosis and treatment solutions.

Technological Advancements in Vision Correction

Innovations such as toric intraocular lenses (IOLs), wavefront-guided LASIK, and customized contact lenses are improving treatment accuracy and patient outcomes. These advancements enhance adoption rates and expand the market scope.

Increasing Adoption of Laser Eye Surgeries

Procedures like LASIK and SMILE are gaining popularity due to their effectiveness, quick recovery time, and long-term benefits. The growing preference for surgical correction is significantly contributing to market expansion.

Rising Awareness and Early Diagnosis

Improved awareness about eye health and the importance of early detection has led to increased screening rates. Early diagnosis enables timely treatment, boosting demand for ophthalmic products and services.

Aging Population

The global rise in the elderly population is a major growth driver, as age-related changes in the eye increase the likelihood of astigmatism and other vision disorders. This demographic trend fuels sustained demand for corrective solutions.

Expansion of Eye Care Infrastructure

Growth in ophthalmic clinics, optical retail chains, and specialized eye care centers has improved accessibility to diagnosis and treatment. This expansion supports higher patient volumes and market growth.

Increasing Demand for Contact Lenses and Eyewear

The rising preference for convenient and aesthetic vision correction options, including toric contact lenses and advanced spectacles, is accelerating product adoption and boosting market revenues.

Genetic and Environmental Factors

Genetic predisposition and environmental influences, such as eye injuries or corneal changes, contribute to the incidence of astigmatism, thereby increasing the patient pool and treatment demand.

Investment in R&D and Product Innovation

Significant investments by key players in research and development are leading to new product launches and improved treatment modalities, strengthening market competitiveness and growth potential.

DelveInsight's "Astigmatism Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of the Astigmatism, historical and forecasted epidemiology as well as the Astigmatism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Astigmatism market report provides current treatment practices, emerging drugs, Astigmatism market share of the individual therapies, current and forecasted Astigmatism market Size from 2022 to 2036 segmented by seven major markets. The Report also covers current Astigmatism treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Astigmatism market.

Astigmatism Disease Understanding and Treatment Algorithm

Astigmatism is a common refractive error of the eye in which the cornea or lens has an irregular shape, preventing light from focusing evenly on the retina. Instead of having a perfectly round curvature, the cornea is shaped more like an oval, leading to blurred or distorted vision at all distances.

Astigmatism can occur alone or alongside other refractive errors such as myopia (nearsightedness) or hyperopia (farsightedness). It is typically present from birth but may also develop later due to eye injury, surgery, or disease. The condition is generally not progressive but can change gradually over time.

There are two main types:

• Corneal astigmatism – caused by irregularities in the cornea
• Lenticular astigmatism – caused by irregularities in the eye’s lens

Astigmatism is highly prevalent worldwide and is one of the leading causes of visual impairment, but it is easily manageable with appropriate corrective measures.

Astigmatism Symptoms

Symptoms of astigmatism can vary depending on severity, but commonly include:

• Blurred or distorted vision at both near and far distances
• Eye strain or discomfort, especially after prolonged visual tasks
• Frequent headaches due to visual stress
• Difficulty seeing at night (poor night vision)
• Squinting to improve clarity
• Double vision (in some cases)

In children, symptoms may be subtle and can include:

• Poor academic performance
• Frequent eye rubbing
• Lack of attention due to visual discomfort

Mild astigmatism may not produce noticeable symptoms, which is why routine eye examinations are important for early detection.

Astigmatism Diagnosis

Astigmatism is diagnosed through a comprehensive eye examination conducted by an optometrist or ophthalmologist. Key diagnostic methods include:

1. Visual Acuity Test

Measures how clearly a person can see at various distances using an eye chart.

2. Refraction Test

Determines the exact prescription needed to correct vision using a device called a phoropter.

3. Keratometry

Measures the curvature of the cornea to detect irregularities that indicate astigmatism.

4. Corneal Topography

An advanced imaging technique that maps the surface curvature of the cornea in detail, providing precise information about astigmatism severity and type.

5. Slit-Lamp Examination

Uses a specialized microscope to examine the eye’s structures and identify underlying causes.

Early diagnosis is essential for effective management and prevention of complications such as amblyopia (lazy eye), especially in children.

Astigmatism Epidemiology 

The Astigmatism epidemiology section provides insights about the historical and current Astigmatism patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Astigmatism market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings from Astigmatism Epidemiology Forecast and Analysis

The disease epidemiology covered in the report provides historical as well as forecasted Astigmatism epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2022 to 2036.

Astigmatism Drugs Analysis

The drug chapter segment of the Astigmatism report encloses the detailed analysis of Astigmatism marketed drugs and late-stage (Phase-III and Phase-II) Astigmatism pipeline drugs. It also helps to understand the Astigmatism clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Astigmatism Emerging Drugs

Phentolamine Ophthalmic Solution 0.75%: Opus Genetics

Phentolamine ophthalmic solution 0.75% is being developed for impaired night vision rather than for correcting the refractive cylinder of astigmatism. Its relevance to the astigmatism market is that patients experiencing visual disturbances after corneal reshaping procedures, including procedures performed for astigmatism, may experience glare, halos and starbursts. In September 2026, late-stage clinical data reported improvements in night-driving vision, including a higher proportion of treated participants achieving substantial visual-acuity gains compared with placebo.

Key Developments in the Astigmatism Market

• In September 2026, Late-stage studies of 0.75% phentolamine ophthalmic solution reported improvements in night vision, including reductions in glare, halos and starbursts. Some study participants had visual symptoms following corneal reshaping procedures such as LASIK performed for refractive errors including astigmatism.
• In July 2026, the FDA granted 510(k) clearance to HOYA Illumina daily disposable soft contact lenses, including a toric version designed for astigmatism. The FDA decision was dated July 7, 2026.
• In June 2026, FDA clearance was reported for Be Free Day Toric lenses for patients with myopia and astigmatism, expanding multifocal-toric contact-lens options.
• In June 2026, Johnson & Johnson expanded the parameter range of its ACUVUE OASYS 1-Day for Astigmatism daily disposable toric contact lenses in the U.S. and Canada, increasing the range of patients who can potentially receive daily disposable toric correction.
• In June 2026, ZEISS announced successful early implantations of its AT LUCIA toric 721P IOL, designed to correct cataracts and astigmatism simultaneously. The company reported that an early-access clinical trial was underway across six European countries.

Astigmatism Market Outlook

The Astigmatism market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Astigmatism market trends by analyzing the impact of current Astigmatism therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Astigmatism market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Astigmatism market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Astigmatism market in 7MM is expected to witness a major change in the study period 2022-2036.

Astigmatism Drugs Uptake

This section focuses on the rate of uptake of the potential Astigmatism drugs recently launched in the Astigmatism market or expected to get launched in the market during the study period 2022-2036. The analysis covers Astigmatism market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Astigmatism Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Astigmatism market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Astigmatism Clinical Trial Activities

The Astigmatism market report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Astigmatism key players involved in developing targeted therapeutics.

Astigmatism Pipeline Development Activities

The Astigmatism market report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Astigmatism emerging therapies.

Reimbursement Scenario in Astigmatism

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Latest KOL- Views on Astigmatism Market

To keep up with current Astigmatism market trends, we take KOLs and SMEs ' opinion working in the Astigmatism domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Astigmatism market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Astigmatism Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Astigmatism Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Astigmatism Market Report

• The Astigmatism Therapeutics Market Report covers a segment of key events, an executive summary, a descriptive overview, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along Astigmatism Treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current Astigmatism Treatment landscape.
• A detailed review of the Astigmatism Therapeutics Market, historical and forecasted Astigmatism Treatment Market Size, Astigmatism Drugs Market Share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Astigmatism Therapeutics Market Report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Astigmatism Drugs Market.

Astigmatism Market Report Insights

• Astigmatism Patient Population Forecast
• Astigmatism Therapeutics Market Size
• Astigmatism Pipeline Drugs Analysis
• Astigmatism Market Size and Trends
• Astigmatism Therapeutics Market Opportunity (Current and Forecasted)

Astigmatism Market Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI) - enabled Market Research Report
• 11-year forecast
• Astigmatism Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Astigmatism Treatment Addressable Market (TAM)
• Astigmatism Competitive Landscape
• Astigmatism Major Companies Insights
• Astigmatism Price Trends and Analogue Assessment
• Astigmatism Therapies Drug Adoption/Uptake
• Astigmatism Therapies Peak Patient Share Analysis

Astigmatism Market Report Assessment

• Astigmatism Current Treatment Practices
• Astigmatism Unmet Needs
• Astigmatism Clinical Development Analysis
• Astigmatism Emerging Drugs Product Profiles
• Astigmatism Market Attractiveness
• Astigmatism Qualitative Analysis (SWOT and Attribute analysis)

Key Questions Answered in the Astigmatism Treatment Market Report

Astigmatism Therapeutics Market Insights

• What was the Astigmatism Treatment Market Size, the Astigmatism Market Size by therapies, Astigmatism Drugs Market Share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Astigmatism?
• What are the disease risks, burdens, and unmet needs of Astigmatism? 
• What will be the growth opportunities across the 7MM concerning the patient population with Astigmatism?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Astigmatism? What are the current guidelines for treating Astigmatism in the US, Europe, and Japan?

Reasons to Buy the Astigmatism Therapeutics Market Report

• The Astigmatism Therapeutics Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Astigmatism Drugs Market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease Astigmatism Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Astigmatism Drugs Market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the Astigmatism Drugs Market will help devise strategies to help get ahead of competitors.
• Detailed analysis, ranking of class-wise potential current, and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Astigmatism Drugs Market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)   enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.